Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lexaria Bioscience Corp. (LEXX)
Price$14.15Cached quote
Net income
2010
2011
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Oct 31 | 2013 · Aug 31 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $86,380 | $255,397 | $722,738 | $384,543 | $222,610 | $433,287 | $63,639 | $40,718 | $14,702 | $0 | — | — | — | — | — |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 | $215,415 | $199,717 | $408,102 | $33,889 | −$4,897 | −$15,181 | $0 | $302,251 | $0 | $574,494 | $465,911 | $88,856 |
| Gross margin | 99.61% | 98.96% | 225.41% | 71.87% | 75.74% | 56.02% | 89.72% | 94.19% | 53.25% | −12.03% | −103.26% | — | — | — | — | — | — |
| Research & development | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M | $387,074 | $555,730 | $492,864 | $54,185 | $9,024 | $146,466 | $0 | — | — | — | — | — |
| Operating expenses | $12.6M | $6.2M | $6.7M | $6.8M | $6.2M | $4.4M | $4.4M | $7.0M | $2.0M | $1.3M | $2.0M | $1.6M | $645,802 | $538,327 | $826,002 | $1.0M | $641,318 |
| Operating income | −$11.9M | −$5.8M | −$6.5M | −$6.6M | −$5.7M | — | — | — | — | −$1.3M | −$2.0M | −$1.6M | — | — | — | — | — |
| Operating margin | −1,683.01% | −1,239.16% | −7,564.28% | −2,591.67% | −786.85% | — | — | — | — | −3,136.82% | −13,489.80% | — | — | — | — | — | — |
| EBITDA | −$11.8M | −$5.7M | −$6.4M | −$6.5M | −$5.6M | — | — | — | — | −$1.3M | −$2.0M | — | — | — | — | — | — |
| EBITDA margin | −1,675.75% | −1,230.01% | −7,395.95% | −2,551.45% | −771.39% | — | — | — | — | −3,135.30% | −13,489.80% | — | — | — | — | — | — |
| Net income | −$11.9M | −$5.8M | −$6.7M | −$7.3M | −$4.0M | −$4.1M | −$4.2M | −$6.6M | −$1.9M | −$1.3M | −$2.0M | −$1.6M | — | — | — | −$538,226 | −$552,462 |
| Net profit margin | −1,686.00% | −1,248.25% | −7,715.79% | −2,846.28% | −557.19% | −1,062.20% | −1,868.03% | −1,525.36% | −3,031.89% | −3,136.82% | −13,489.80% | — | — | — | — | — | — |
| Basic EPSper basic share | -$9.90 | -$7.05 | -$1.01 | -$1.24 | -$0.95 | -$1.47 | -$1.50 | -$2.70 | -$0.90 | -$0.90 | -$1.20 | -$3.82 | -$0.55 | -$0.55 | -$0.55 | -$1.09 | — |
| Diluted EPSper diluted share | -$0.66 | -$0.47 | -$1.01 | -$1.24 | -$0.95 | -$1.47 | -$1.50 | -$2.70 | -$0.90 | -$0.90 | -$1.20 | -$3.82 | -$0.55 | -$0.55 | -$0.55 | -$1.09 | -$1.09 |
Owners
Reported shareholders
≈3.75%of listed shares
BUNKA CHRISTOPHER929K shares · Mar 17, 2026
View holders
| Holder | % owned |
|---|---|
BUNKA CHRISTOPHER | ≈3.75%929K shares |
Invenomic Capital Management LP | ≈1.39%345.69K shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈1.20%298.44K shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈1.01%250.42K shares |
CITADEL ADVISORS LLC | ≈0.63%156.95K shares |
TORONTO DOMINION BANK | ≈0.40%100.01K shares |
VANGUARD FIDUCIARY TRUST CO | ≈0.38%94.17K shares |
HRT FINANCIAL LP | ≈0.26%65.05K shares |
DOCHERTY JOHN MARTIN | ≈0.24%59.45K shares |
UBS Group AG | ≈0.19%46.97K shares |
NORTHERN TRUST CORP | ≈0.16%39.83K shares |
STATE STREET CORP | ≈0.16%39.3K shares |
BlackRock, Inc. | ≈0.11%27.45K shares |
StoneX Group Inc. | ≈0.10%25.71K shares |
Krilogy Financial LLC | ≈0.10%24.15K shares |
XTX Topco Ltd | ≈0.09%22.3K shares |
Virtu Financial LLC | ≈0.08%18.9K shares |
RENAISSANCE TECHNOLOGIES LLC | ≈0.07%16.5K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | ≈0.06%15.26K shares |
Vontobel Holding Ltd. | ≈0.06%15.19K shares |
Percentages use 24.79M shares of this listed class outstanding on May 31, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 30, 2025Form 4 | BUNKA CHRISTOPHERDirector | Buycommon shares · indirect | 11.9K | $0.91 | $10.8K | 281.9K |
| Jul 29, 2025Form 4 | BUNKA CHRISTOPHERDirector | Buycommon shares · indirect | 15.6K | $0.92 | $14.4K | 270.0K |
| Jul 29, 2025Form 4 | McKechnie William EdwardDirector | Buycommon shares | 5.0K | $0.91 | $4.5K | 18.2K |
| Jul 29, 2025Form 4 | DOCHERTY JOHN MARTINPresident & CSO | Buycommon shares | 5.4K | $0.93 | $5.0K | 5.4K |
| Jul 29, 2025Form 4 | Carle VanessaSecretary | Buycommon shares | 750 | $0.91 | $682.50 | 750 |